Identification of novel leishmanicidal molecules by virtual and biochemical screenings targeting Leishmania eukaryotic translation initiation factor 4A

PLoS Negl Trop Dis. 2018 Jan 18;12(1):e0006160. doi: 10.1371/journal.pntd.0006160. eCollection 2018 Jan.

Abstract

Leishmaniases are neglected parasitic diseases in spite of the major burden they inflict on public health. The identification of novel drugs and targets constitutes a research priority. For that purpose we used Leishmania infantum initiation factor 4A (LieIF), an essential translation initiation factor that belongs to the DEAD-box proteins family, as a potential drug target. We modeled its structure and identified two potential binding sites. A virtual screening of a diverse chemical library was performed for both sites. The results were analyzed with an in-house version of the Self-Organizing Maps algorithm combined with multiple filters, which led to the selection of 305 molecules. Effects of these molecules on the ATPase activity of LieIF permitted the identification of a promising hit (208) having a half maximal inhibitory concentration (IC50) of 150 ± 15 μM for 1 μM of protein. Ten chemical analogues of compound 208 were identified and two additional inhibitors were selected (20 and 48). These compounds inhibited the mammalian eIF4I with IC50 values within the same range. All three hits affected the viability of the extra-cellular form of L. infantum parasites with IC50 values at low micromolar concentrations. These molecules showed non-significant toxicity toward THP-1 macrophages. Furthermore, their anti-leishmanial activity was validated with experimental assays on L. infantum intramacrophage amastigotes showing IC50 values lower than 4.2 μM. Selected compounds exhibited selectivity indexes between 19 to 38, which reflects their potential as promising anti-Leishmania molecules.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphatases / analysis
  • Adenosine Triphosphatases / antagonists & inhibitors
  • Antiprotozoal Agents / isolation & purification*
  • Antiprotozoal Agents / pharmacology*
  • Binding Sites
  • Drug Evaluation, Preclinical / methods*
  • Eukaryotic Initiation Factor-4A / antagonists & inhibitors*
  • Eukaryotic Initiation Factor-4A / chemistry
  • Inhibitory Concentration 50
  • Leishmania infantum / drug effects*
  • Leishmania infantum / enzymology*
  • Models, Molecular
  • Molecular Docking Simulation
  • Parasitic Sensitivity Tests

Substances

  • Antiprotozoal Agents
  • Eukaryotic Initiation Factor-4A
  • Adenosine Triphosphatases

Grants and funding

This work received financial support from the Institut Pasteur PTR program (grant PTR426), and partially from the Ministry of Higher Education and Research in Tunisia (LR00IPT04 & LR11IPT04; IG), MN received financial support from the Investissement d’Avenir bioinformatics programme (Grant Bip:Bip ANR-BINF-03-01) and BayCellS FP7-IDEAS-ERC 294809, NKT and JB are supported by a Centre National de la Recherche Scientifique (CNRS), HeliDEAD grant [ANR-13- BSV8-0009-01] from the Agence Nationale de la Recherche and the Initiative d’Excellence program from the French State [DYNAMO, ANR-11-LABX-0011-01]. EHS received support from the UNESCO-L’Oréal “For Women in Science” international fellowship and the Institut Pasteur International Network (Calmette and Yersin programme). The non commercial compounds were obtained from Dr. Laïla El Kihel from Université de Caen de Basse-Normandie, Centre d’Études et de Recherche sur le Médicament de Normandie (CERMN), UFR des Sciences Pharmaceutiques, for the minimal costs of shipping fees. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.